Elly Gerald Stoica

Array ( [id] => 13699969 [patent_doc_number] => 20170360939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => Liquid Formulation of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment [patent_app_type] => utility [patent_app_number] => 15/637583 [patent_app_country] => US [patent_app_date] => 2017-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14088 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15637583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12239947 [patent_doc_number] => 20180072808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'HUMANIZED ANTI-OX40 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/635847 [patent_app_country] => US [patent_app_date] => 2017-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 59 [patent_no_of_words] => 55487 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15635847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118813 [patent_doc_number] => 20180002399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES' [patent_app_type] => utility [patent_app_number] => 15/631180 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 27504 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092550 [patent_doc_number] => 20170349643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/620211 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 58163 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15620211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13914993 [patent_doc_number] => 10201592 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-12 [patent_title] => Compositions and methods for treating mesothelioma post-surgery [patent_app_type] => utility [patent_app_number] => 15/616393 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 26297 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926421 [patent_doc_number] => 20190298848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => ANTIBODY FUSION PROTEINS FOR DRUG DELIVERY [patent_app_type] => utility [patent_app_number] => 16/307448 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14230561 [patent_doc_number] => 20190127453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => AN ANTI-C5 ANTIBODY DOSING REGIMEN [patent_app_type] => utility [patent_app_number] => 16/306705 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12490077 [patent_doc_number] => 09994637 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Method of treating CD155 expressing cancers [patent_app_type] => utility [patent_app_number] => 15/611134 [patent_app_country] => US [patent_app_date] => 2017-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56825 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15611134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14594179 [patent_doc_number] => 10350266 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Method of treating cancer with a multiple integrin binding Fc fusion protein [patent_app_type] => utility [patent_app_number] => 15/608715 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 37744 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15608715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343619 [patent_doc_number] => 20200308269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => INTERLEUKIN-17 PATHWAY INHIBITOR FOR THE TREATMENT OF CHRONIC HPV INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/303824 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942105 [patent_doc_number] => 20170246257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'POSTPRANDIAL GASTROKINETIC AGENT' [patent_app_type] => utility [patent_app_number] => 15/596736 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 7763 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030857 [patent_doc_number] => 20170320957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'Methods of Inhibiting Activity Using Anti-CD27 Antibodies' [patent_app_type] => utility [patent_app_number] => 15/596609 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 28326 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14641083 [patent_doc_number] => 10365278 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-30 [patent_title] => Pharmaceuticals and methods for treating hypoxia and screening methods therefor [patent_app_type] => utility [patent_app_number] => 15/594454 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 59 [patent_no_of_words] => 27123 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15594454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306393 [patent_doc_number] => 20190142900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => COMPOSITIONS OF MUSCLE STIMULATED MYOKINES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/300472 [patent_app_country] => US [patent_app_date] => 2017-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16300472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12606672 [patent_doc_number] => 20180094054 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => ANTIBODIES THAT BIND CELL SURFACE GRP78 AND THEIR USE FOR DETECTION OF CANCER [patent_app_type] => utility [patent_app_number] => 15/590379 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36002 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15590379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15281789 [patent_doc_number] => 10513549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => Cleavage-activatable interferon-alpha proprotein [patent_app_type] => utility [patent_app_number] => 15/589464 [patent_app_country] => US [patent_app_date] => 2017-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 20735 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 185 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15589464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11993986 [patent_doc_number] => 20170298141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/581214 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 40232 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15581214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16769794 [patent_doc_number] => 10980877 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen [patent_app_type] => utility [patent_app_number] => 16/096990 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 42134 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096990 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821523 [patent_doc_number] => 11426447 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Neuregulin for the treatment of tumors of the nervous system [patent_app_type] => utility [patent_app_number] => 15/999851 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15790 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16550846 [patent_doc_number] => 10884000 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-05 [patent_title] => Method of monitoring the efficacy of the anti-clever-1 therapy in cancer [patent_app_type] => utility [patent_app_number] => 16/093349 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3728 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16093349 [rel_patent_id] =>[rel_patent_doc_number] =>)